Ventyx Biosciences, Inc.

Good day, and thank you for standing by. Welcome to the VINTEX Bioscientists First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Mr. Marty Oster. Please go ahead.

Thank you, operator. Good afternoon, everyone. Thanks for joining the call today. Welcome to Vendix Biosciences conference call and webcast where we'll be discussing our first quarter 2022 financial results and providing a business update. As a reminder, the company's most recent investor presentation can be found on our website at www.vendixbio.com under the investor tab of the news and events section. Before we begin today, I'd like to remind everyone that this conference call webcast will contain forward-looking statements about the company, including statements about the timing of commencement, enrollment, and completion of clinical trials, the anticipated timing of release of clinical trial data, and the expected timeframe for funding operations with current cash, cash equivalents, and marketable securities. These statements are subject to risks and uncertainties that could cause actual results to differ, Please note that these forward-looking statements reflect our opinions only as of the date of this call, and we undertake no obligation to revise or publicly release the results of any revisions to these forward-looking statements in light of new information at future events. Factors that could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Form 10-Q for the first quarter of 2022, which we expect to file later this afternoon. With that, I will hand the call over to Dr. Raju Mohan, Vintix Co-founder and CEO. Raju, please go ahead.

Thanks, Marty, and thanks to everyone for joining our call this afternoon. So let me briefly run through this afternoon's agenda. We'll start with a business update and then present an overview of the company's pipeline, followed by recent highlights. And then going to hand the call back to Marty for a brief overview of our first quarter financial results, before we open the discussion, the call for Q&A. Before we begin, however, I want to take a minute to formally introduce Bill Sanborn. And we announced his news earlier this week, joined the Ventix leadership team as president and chief medical officer. As many of you know, Bill is a highly accomplished clinician and a renowned expert in the field of autoimmune and inflammatory diseases, but clearly inflammatory bowel disease, or IBD. Bill has been closely involved in the development of a number of approved therapies in the INI space, in the immunology space, both biologics and small molecules. As chairman of our clinical advisory board for the past few years, Bill has played a key role in developing and shaping our clinical strategy, And now, in his new role as both resident, but more importantly for us as a CMO, he will lead our CIMDEV team, our clinical development team, as we advance our portfolio to target multiple immune-mediated diseases. So, welcome to the Ventix team, Bill. And I appreciate if you would say a few words before we move ahead with the rest of the agenda.